A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)

Phase 1 Completed 196 enrolled Terns, Inc.

RandomizedSequentialOpen-labelBasic science

Summary

The goal of the study is to learn what happens to different doses and forms of TERN-701 in a healthy person's body over time. Researchers will compare what happens to different doses and forms of TERN-701 in a person's body over time when given with or without food, or with or without other medications. The goal of the study is to learn: * What happens to different doses of TERN-701 in a person's body over time when it is given with or without food, or with or without other medications. * About the safety of TERN-701 and if people tolerate it

Timeline

Start: 2023-12-21
Primary completion: 2026-06-30
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosentan	Other / unclassified	125 mg	Oral
Subject	Digoxin	Other / unclassified	0.25 mg	Oral
Subject	Itraconazole	Small molecule	200 mg	Oral
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	Montelukast	Other / unclassified	10 mg	Oral
Subject	Omeprazole	Other / unclassified	40 mg	Oral
Subject	Pravastatin	Small molecule	40 mg	Oral
Subject	Quinidine	Small molecule	300 mg	Oral
Subject	Rabeprazole	Small molecule	20 mg	Oral
Subject	Rosuvastatin	Small molecule	10 mg	Oral
Subject	TERN-701	Unknown	—	Oral
Subject	Warfarin	Small molecule	5 mg	Oral

Indications

No indication recorded.